Screener
AOCI at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001070081-26-000012
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 3,049,569 | 3,104,080 |
| Stockholders’ deficit: | ||
| Common stock, $0.001 par value. Authorized 250,000,000 shares; issued and outstanding 82,882,024 shares at March 31, 2026. Authorized 250,000,000 shares; issued and outstanding 81,474,366 shares at December 31, 2025. | 81 | 80 |
| Additional paid-in capital | 2,778,026 | 2,748,335 |
| Accumulated other comprehensive income | 8,466 | 10,501 |
| Accumulated deficit | (2,967,038) | (2,964,229) |
| Total stockholders’ deficit | (180,465) | (205,313) |
| Total liabilities and stockholders’ deficit | $2,869,104 | $2,898,767 |
Item 1. Financial Statements (unaudited)
FAQ
- What is PTC Therapeutics's AOCI?
- PTC Therapeutics (PTCT) reported AOCI of $8.47M in Q1 2026.
- How has PTC Therapeutics's AOCI changed year-over-year?
- PTC Therapeutics's AOCI increased by 160.7% year-over-year, from -$13.95M to $8.47M.
- What is the long-term trend for PTC Therapeutics's AOCI?
- Over 5 years (2020 to 2025), PTC Therapeutics's AOCI has grown at a -29.7% compound annual growth rate (CAGR), from -$60.96M to $10.5M.
- What does AOCI mean?
- Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.
Ask your AI about PTC Therapeutics's aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude